Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Tahami Monfared AA, Ye W, Sardesai A, Folse H, Chavan A, Kang K, Zhang Q

Open source

DOI
10.1007/s40120-023-00460-1
Published
2023 Jun
Container
Neurology and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s40120-023-00460-1,
  title = {Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.},
  author = {Tahami Monfared AA and Ye W and Sardesai A and Folse H and Chavan A and Kang K and Zhang Q},
  year = {2023},
  journal = {Neurology and therapy},
  doi = {10.1007/s40120-023-00460-1},
  url = {https://doi.org/10.1007/s40120-023-00460-1}
}

RIS

TY  - JOUR
TI  - Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
AU  - Tahami Monfared AA
AU  - Ye W
AU  - Sardesai A
AU  - Folse H
AU  - Chavan A
AU  - Kang K
AU  - Zhang Q
PY  - 2023
JO  - Neurology and therapy
DO  - 10.1007/s40120-023-00460-1
UR  - https://doi.org/10.1007/s40120-023-00460-1
ER  - 

APA

AA, T. M., W, Y., A, S., H, F., A, C., K, K., & Q, Z. (2023). Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.. Neurology and therapy. https://doi.org/10.1007/s40120-023-00460-1

Source records